In most cases of acromegaly, this excessive growth hormone production stems from a noncancerous tumor in the pituitary gland. However, in rarer instances, the disease can be triggered by tumors ...

Endocrinology specialist Dr Preethi Dissanayake discusses this uncommon presentation, in the latest in our series on ...

Acromegaly is a life-shortening disease where much of the morbidity is caused by insulin resistance, lipotoxicity, and cardiovascular events. Current therapies for acromegaly are associated with ...

The novel consensus statement highlights current analytical pitfalls and the need to optimize disease control in acromegaly. Acromegaly is a serious endocrine disease associated with increased ...

The following is a summary of “Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with ...

Somatostatin analogues are clinically used for the treatment of acromegaly and have the benefit of both reduction of tumor size and hormonal control of this disease. Because pituitary corticotroph ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Crinetics Pharmaceuticals is set for a fall 2025 launch of paltusotine, with strong Wall Street support despite being ...

Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in Pre-Registration for Acromegaly.

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on CRNX stock, giving a Buy rating yesterday.Stay Ahead of the ...